On Wednesday, officials from the state Food and Drugs Administration (FDA) carried out a significant operation in Vasai. They seized Ayurvedic drugs, raw materials, and labels worth ₹1.4 crore from three different locations. These items were being produced without the necessary local license, which is a serious violation of the law.
The main company involved in this illegal activity is Gaharwar Pharma Products Pvt Ltd. This company is legally allowed to manufacture Ayurvedic drugs in Haryana. However, it was discovered that they were also producing these drugs in Vasai without getting the proper local license.
FDA officials explained that Gaharwar Pharma had a loan license for manufacturing Ayurvedic drugs in Haryana. However, they had surrendered this license to the Directorate of Ayush on May 14. Despite this, the company continued to manufacture drugs in Vasai using the same Haryana license. This is clearly against the rules, as each location where drugs are manufactured must have its own license.
The FDA took this matter very seriously. They conducted raids at three locations in Vasai and confiscated a large quantity of drugs and raw materials. The seized items included finished Ayurvedic products, raw materials used in their production, and various labels.
Officials from the FDA stated that manufacturing drugs without a valid license poses a significant risk to public health. The quality and safety of these drugs cannot be guaranteed if they are produced without proper oversight and regulation. The FDA’s actions were aimed at protecting consumers and ensuring that all drugs on the market are safe and effective.
The seized drugs and materials are now in the custody of the FDA, and further investigations are underway. The authorities are looking into how long this illegal manufacturing has been going on and whether there are any other locations involved.
This case highlights the importance of proper licensing and regulation in the pharmaceutical industry, including Ayurvedic medicines. Licenses ensure that manufacturers follow strict guidelines and standards, which are essential for the safety and efficacy of the drugs they produce. When companies bypass these regulations, they put consumers at risk.
The FDA has urged the public to be cautious and vigilant about the medicines they purchase. It is important to buy drugs from reputable sources and to check for proper labeling and licensing information. If there are any doubts or concerns about the authenticity of a product, consumers should report them to the authorities.
This incident in Vasai is a reminder of the ongoing efforts needed to regulate the pharmaceutical industry and to protect public health. The FDA will continue to monitor and take action against any illegal activities in the manufacturing and distribution of drugs.
In conclusion, the seizure of ₹1.4 crore worth of Ayurvedic drugs in Vasai serves as a stark warning to other manufacturers who might consider operating without the necessary licenses. The FDA’s swift action demonstrates their commitment to upholding the law and ensuring the safety of consumers. This case also underscores the need for consumers to stay informed and vigilant about the medicines they use.
